<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&amp;nbsp;&lt;span&gt; &lt;/span&gt;&lt;/p&gt;&lt;table cellspacing="0" cellpadding="2" border="0" id="schedule" summary="This table shows the date, time, and location of the meeting" style="width: 643px"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th valign="top" bgcolor="#cccccc" align="left" id="a1" style="width: 59px"&gt;Center&lt;/th&gt;&lt;th valign="top" bgcolor="#cccccc" align="left" id="a2" style="width: 108px"&gt;Date&lt;/th&gt;&lt;th valign="top" bgcolor="#cccccc" align="left" id="a3" style="width: 163px"&gt;Time&lt;/th&gt;&lt;th valign="top" bgcolor="#cccccc" align="left" id="a4" style="width: 193px"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" height="61" headers="a1" style="width: 59px"&gt;CDER&lt;/td&gt;&lt;td valign="top" headers="a2" style="width: 108px"&gt;May 10, 2012&lt;/td&gt;&lt;td valign="top" headers="a3" style="width: 163px"&gt;8:00 a.m. to 5:00 p.m.&lt;/td&gt;&lt;td valign="top" headers="a4" style="width: 193px"&gt;&lt;p&gt;DoubleTree by Hilton Hotel&lt;/p&gt;&lt;div&gt;Washington DC - Silver Spring&lt;/div&gt;&lt;div&gt;The Ballrooms&lt;/div&gt;&lt;div&gt;8727 Colesville Road&lt;/div&gt;Silver Spring, Maryland&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;div&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;b&gt;Agenda&lt;/b&gt;&lt;/div&gt;&lt;div&gt;On May 10, 2012, the committee will discuss the safety and efficacy  of new drug application (NDA) 22-529 (lorcaserin hydrochloride) tablets, manufactured by Arena Pharmaceuticals, Inc., as an adjunct to diet and exercise for weight management in patients with a body mass index (BMI) equal to or greater than 30 kilograms (kg) per square meter or a BMI equal to or greater than 27 kg per square meter if accompanied by weight-related co-morbidities.&lt;/div&gt;&lt;div&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&lt;b&gt;Meeting Materials&lt;/b&gt;&lt;/div&gt;&lt;div&gt;FDA  intends to make background material available to the public no later  than 2 business days before the meeting.&amp;nbsp; If FDA is unable to post the  background material on its Web site prior to the meeting, the background  material will be made publicly available at the location of the  advisory committee meeting, and the background material will be posted  on FDA&amp;rsquo;s Web site after the meeting.&amp;nbsp;&lt;br /&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;Background Material &lt;/strong&gt;&lt;/div&gt;&lt;ul&gt;&lt;li&gt;&lt;a target="" href="http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm285142.htm"&gt;&lt;span style="FONT-WEIGHT: normal; FONT-SIZE: 9pt; FONT-FAMILY: Arial,Helvetica,sans-serif"&gt;2012  Meeting Materials, Endocrinologic and Metabolic Drugs Advisory Committee &lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;b&gt;Public Participation Information&lt;/b&gt;&lt;/div&gt;&lt;div&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&amp;nbsp;&lt;/div&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before April 26, 2012.&lt;/li&gt;&lt;li&gt;Oral  presentations from the public will be scheduled between approximately 1  p.m. to 2 p.m. on May 10, 2012. Those desiring to make formal oral  presentations should notify the contact person and submit a brief  statement of the general nature of the evidence or arguments they wish  to present, the names and addresses of proposed participants, and an  indication of the approximate time requested to make their presentation  on or before April 18, 2012.&lt;/li&gt;&lt;/ul&gt;&lt;div&gt;Time allotted for each  presentation may be limited.&amp;nbsp;If the number of registrants requesting to  speak is greater than can be reasonably accommodated during the  scheduled open public hearing session, FDA may conduct a lottery to  determine the speakers for the scheduled open public hearing  session.&amp;nbsp;The contact person will notify interested persons regarding  their request to speak by April 19, 2012.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;b&gt;Webcast Information&lt;/b&gt;&lt;/div&gt;&lt;div&gt;CDER will not be providing a webcast of the Endocrinologic and Metabolic Drugs Advisory  Committee meeting.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div align="center"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;b&gt;Contact Information&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&lt;ul&gt;&lt;li&gt;Paul Tran, R.Ph.&lt;br /&gt;Center for Drug Evaluation and Research&lt;br /&gt;Food and Drug Administration&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;WO31-2417&lt;br /&gt;Silver Spring, MD&amp;nbsp;20993&lt;br /&gt;Phone: 301-796-9001&lt;br /&gt;Fax: 301-847-8533&lt;br /&gt;E-mail: &lt;a href="mailto:EMDAC@fda.hhs.gov"&gt;&lt;u&gt;&lt;font color="#0000ff"&gt;EMDAC@fda.hhs.gov&lt;/font&gt;&lt;/u&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington DC area)- follow the prompts to the desired center or product area&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;A  notice in the Federal Register about last minute modifications that  impact a previously announced advisory committee meeting cannot always  be published quickly enough to provide timely notice.&amp;nbsp;Therefore, you  should always check the agency&amp;rsquo;s Web site and call the appropriate  advisory committee hot line/phone line to learn about possible  modifications before coming to the meeting.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;Persons  attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency  is not responsible for providing access to electrical outlets.&amp;nbsp;FDA  welcomes the attendance of the public at its advisory committee meetings  and will make every effort to accommodate persons with physical  disabilities or special needs. If you require special accommodations due  to a disability, please contact Paul Tran at (301) 796-9001 at least 7  days in advance of the meeting.&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;FDA is committed to the orderly conduct of its advisory committee meetings.&amp;nbsp;Please visit our Web site at &lt;a href="http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm"&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/div&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
